We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)

This study is currently recruiting participants.
Verified July 2017 by Axsome Therapeutics, Inc.
ClinicalTrials.gov Identifier:
First Posted: July 21, 2017
Last Update Posted: July 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Axsome Therapeutics, Inc.
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Condition Intervention Phase
Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor Drug: AXS-05 Drug: Bupropion Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Resource links provided by NLM:

Further study details as provided by Axsome Therapeutics, Inc.:

Primary Outcome Measures:
  • Cohen-Mansfield Agitation Inventory (CMAI) [ Time Frame: 5 weeks ]
    Change from Baseline to Week 5 in the CMAI

Estimated Enrollment: 435
Actual Study Start Date: July 13, 2017
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AXS-05
AXS-05 tablets taken by mouth for 5 weeks.
Drug: AXS-05
Active Comparator: Bupropion
Bupropion tablets taken by mouth for 5 weeks.
Drug: Bupropion
Placebo Comparator: Placebo
Placebo tablets taken by mouth for 5 weeks.
Drug: Placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion Criteria:

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03226522

Contact: Axsome Clinical Trials +1 (212) 332-3241 ADVANCE-1@axsome.com

United States, Florida
Meridian Research Recruiting
Brooksville, Florida, United States, 34601
Contact: Research Director         
Sponsors and Collaborators
Axsome Therapeutics, Inc.
  More Information

Responsible Party: Axsome Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03226522     History of Changes
Other Study ID Numbers: AXS-05-AD-301
First Submitted: July 20, 2017
First Posted: July 21, 2017
Last Update Posted: July 25, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors